Scoping Review on the Use of Drugs Targeting JAK/STAT Pathway in Atopic Dermatitis, Vitiligo, and Alopecia Areata.

Montilla, Ana M; Gómez-García, Francisco; Gómez-Arias, Pedro J; Gay-Mimbrera, Jesús; Hernández-Parada, Jorge; Isla-Tejera, Beatriz; Ruano, Juan

Montilla, Ana M; Gómez-García, Francisco; Gómez-Arias, Pedro J; Gay-Mimbrera, Jesús; Hernández-Parada, Jorge; Isla-Tejera, Beatriz; Ruano, Juan.

Afiliación

Montilla AM; Immune-mediated Inflammatory Skin Diseases Group, IMIBIC/Reina Sofía University Hospital/University of Córdoba, 14004, Córdoba, Spain.
Gómez-García F; School of Medicine, University of Córdoba, 14004, Córdoba, Spain.
Gómez-Arias PJ; Immune-mediated Inflammatory Skin Diseases Group, IMIBIC/Reina Sofía University Hospital/University of Córdoba, 14004, Córdoba, Spain.
Gay-Mimbrera J; Department of Dermatology, Reina Sofía University Hospital, 14004, Córdoba, Spain.
Hernández-Parada J; Immune-mediated Inflammatory Skin Diseases Group, IMIBIC/Reina Sofía University Hospital/University of Córdoba, 14004, Córdoba, Spain.
Isla-Tejera B; Department of Dermatology, Reina Sofía University Hospital, 14004, Córdoba, Spain.
Ruano J; Immune-mediated Inflammatory Skin Diseases Group, IMIBIC/Reina Sofía University Hospital/University of Córdoba, 14004, Córdoba, Spain.

Dermatol Ther (Heidelb) ; 9(4): 655-683, 2019 Dec.

Article en En | MEDLINE | ID: mdl-31606872

Palabras clave

Alopecia areata; Atopic dermatitis; Baricitinib; Cerdulatinib; Immune-mediated inflammatory skin diseases; JAK/STAT pathway; Ruxolitinib; Tofacitinib; Upadacitinib; Vitiligo

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Guideline / Observational_studies / Systematic_reviews Idioma: En Revista: Dermatol Ther (Heidelb) Año: 2019 Tipo del documento: Article País de afiliación: España Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google